Worldwide $60.5 Billion Market for In Vitro Diagnostic (IVD) Tests, 2021 - Research and Markets

DUBLIN, Apr 6, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 10th Edition" report to their offering.

The global IVD market is currently 60.5 billion dollars.

The Worldwide Market for In Vitro Diagnostic Tests, has been updated for two decades in ten editions, keeping readers informed about developments in all areas of the ivd industry, around the world, in one volume. The 1,600-page report provides market size estimates and projections for the entirety of the clinical diagnostics testing market. It also tracks hundreds of competitors, notes significant partnerships, distribution deals and acquisitions and defines the market share situation for the in vitro diagnostic market and competitive analysis for many segments.

The market for IVD reagents, kits, and instruments will grow, but in a complex pattern that involves challenges to growth in traditional categories and reliable large markets combined with opportunities in novel tests and growth nations. This is the finding of a comprehensive study on IVD, released every 2 years and analyzing every segment of IVD testing with trend analysis, market forecasts and company profiles.

A variety of factors are driving growth in IVD sales:

- Aging Population
- Disease Incidence, Notably Cancer and Infectious Disease
- New Biomarkers
- Increased Insurance and Spending in Emerging Nations

Published every two years, this report estimates the current in vitro diagnostics market size and forecasted market size to 2021 for defined segments of the IVD market and various sub-segments, including:

- Molecular Assays (Infectious Disease, Blood Screening, Inherited Diseases, Oncology, Pharmacodiagnostics, Tissue Typing, Prenatal)
- Clinical Chemistry and "Core Lab" Markets (including sub segment revenues for General Chemistries, Workstations, Analyzers Blood Gases, Urinalysis, Critical Care)
- Point-of-Care Testing (POC), (Professional and Self-Testing, Glucose Testing, Pregnancy Tests, drugs of abuse, HIV, H. pylori, Other, OTC/Self Total, Professional POC, Cardiac Markers, Drugs of Abuse, HbA1c, Pregnancy, Other)
- Microbiology and Virology by Test Type (Immunoassays, ID/AST, Infectious Diseases - DNA; ID/AST: Panels and Reagents, automated; Panels and Reagents, manual; Blood Culture; Chromogenic Media; Rapid Micro; Supplies)
- Blood Banking (Grouping, Immunoassay Screens, NAT Screens)
- Tissue-Based Testing - Histology and Cytology (Pap, ISH, IHC, HPV)
- Infectious Disease Immunoassay Testing (Hepatitis, HIV, STDs, TORCH, Respiratory, Sepsis, Parasitology, Mycology, Others)
- Hematology
- Molecular Tests in Infectious Diseases (HAI, HIV, Hepatitis, GC/Chlamydia, Respiratory, Organism ID, Mycobacteria, TB, Others
- Non-Infectious Disease Immunoassay Sales by Analyte Type (Cardiac markers, Tumor markers, Diabetes/HbA1c, Autoimmune, Allergy, Thyroid, Proteins, Anemia, Fertility, Therapeutic drugs, Tox/Drugs of abuse, Vitamin D)
- Coagulation Tests (Lab-Based, POC, Genetic Markers)
- Sequencing and Flow Cytometry

Companies in the IVD Market

- Abbott Diagnostics
- Alere Inc
- Beckman Coulter, Inc. / Danaher
- Becton, Dickinson and Company (BD)
- bioMérieux Inc.
- Bio-Rad Laboratories
- Hologic
- Instrumentation Laboratory (IL)
- Ortho Clinical Diagnostics (OCD)
- QIAGEN N.V
- Roche Diagnostics
- Siemens Healthineers
- Sysmex Corporation
- Thermo FisherScientific
- Werfen Group S.A.

Next Tier IVD Companies: growth-oriented companies that have significant presence in one or several areas are profiled and their new products and strategies discussed in the report. Among these:

Affymetrix Inc.
Cepheid
ERBA Diagnostics, Inc
DiaSorin S.p.A
Illumina
Luminex Corporation
Menarini Diagnostics.
Mindray Medical International Limited
Myriad Genetics
Perkin Elmer, Inc. (PE)
Quidel Corporation
Randox Laboratories Ltd
Royal Philips
TOSOH Corporation
Trinity Biotech
Wako Pure Chemical Industries

Specialist Companies: While these companies focus on one segment of the IVD market, they can often be dominant in the They are important to watch because they can often develop products in new areas of testing and move categories.

Molecular Specialists
Blood Banking Specialists
Point of Care Specialists
Prenatal Test Service Providers
Quality Control and Pretreatment Specialists
CoagulationSpecialists
Histology and Cytology Specialists
Microbiology Specialists
IT SolutionsCompanies
CTC and Liquid Biopsy Specialists

None of the above would be happening without significant forces in the market driving them. This updated report presents the trends, technologies, customer needs and major suppliers with an eye on how they are shaping the IVD industry, including the following trends:

- Top 20 Companies and Niche Players 2012-2016
- Acquisitions in the IVD Market
- NGS, LC-MS and Other Novel Testing
- Lab Market Segmentation (Hospital, Independent, POLs)
- Emerging Markets
- Digital Technology, IT and Big Data
- Gene Editing
- Wearables
- Europe and Austerity
- Status of LDTs
- State of Biomarker Discovery
- Test Services Trend
- Distribution Agreements
- Role of Sequencing
- Non-Blood Sampling
- LDT Regulatory Picture
- New Product Launches
- Near-Patient Testing
- DTC Testing
- New Testing Venues

For more information about this report visit http://www.researchandmarkets.com/research/h8kqv7/the_worldwide

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[e-mail]

For E.S.T Office Hours Call [phone]
For U.S./CAN Toll Free Call [phone]
For GMT Office Hours Call [phone]

U.S. Fax: [phone]
Fax (outside U.S.): [phone]